Emovi Shares Results of Clinical Trial of KneeKG

Emovi Inc. has shared positive results from a randomized, controlled trial involving KneeKG, Emovi’s flagship medical device and one of the first devices that enables healthcare professionals to accurately assess patients’ knees in 3D while the patient is moving and weight-bearing. The results indicate that integrating data from an objective biomechanical evaluation using KneeKG into the management of knee osteoarthritis patients, can significantly reduce patients’ pain while improving their function and satisfaction levels.
 
Emovi’s clinical study has been accepted for publication by Postgraduate Medicine, a peer-reviewed medical journal established by Charles Mayo MD, founder of the Mayo Clinic. The journal publishes research which supports primary care physicians in solving clinical problems and improving patient care.
 
About the Trial
In the cluster randomized controlled trial, primary care clinics were randomized into three groups. Of the 894 patients referred from 87 clinics, 449 completed the study. At the six-month follow-up appointments, patients in Group 2 and Group 3, the KneeKG groups, reported statistically significant improvement in symptoms, pain, and activities of daily living subscales.  The study also demonstrated a higher engagement of patients in their care in Group 2 and 3.  
 
This pivotal study demonstrated that KneeKG enhances physicians’ capability and knowledge base to immediately pinpoint functional deficits that correlate to the patient’s knee pain. The Knee Kinesiography by KneeKG enables the physician and other healthcare professionals to determine the most appropriate patient specific care to achieve better outcomes and restore optimal knee function which could potentially delay the need for knee replacement as suggested by a previous study.  
 
“These study findings are a huge win for the millions of people suffering from knee pain and for healthcare professionals,” said Michelle Laflamme, CEO of Emovi. “KneeKG is a new level of orthopedic innovation providing real time, quantifiable data that objectively and accurately assesses dynamic knee function, and these results position the device as a solution to improve the current standard of care. It is a non-invasive technology that can identify the true biomechanical deficits impacting knee (dys)function which can guide the development of a targeted, patient specific, non-surgical treatment plan for knee OA that reduces patient pain and improves function of daily activities.”  
 
Osteoarthritis (OA) is the most common joint disorder in many countries, affecting for example 13.9% of adults 25 years and older and 33.6% of people 65 years and older in the United States. In Canada, it affects more Canadians than all other forms of arthritis combined.